{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:43:52Z","timestamp":1787503432120,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T00:00:00Z","timestamp":1360886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1038\/eye.2012.284","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T05:40:21Z","timestamp":1360906821000},"page":"308-319","source":"Crossref","is-referenced-by-count":113,"title":["Acute thyroid eye disease (TED): Principles of medical and surgical management"],"prefix":"10.1038","volume":"27","author":[{"given":"D H","family":"Verity","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G E","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,15]]},"reference":[{"key":"BFeye2012284_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","volume":"129","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell\u2019Unto E, Bartolomei MP et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998; 129: 632\u2013635.","journal-title":"Ann Intern Med"},{"key":"BFeye2012284_CR2","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1210\/jc.2003-030380","volume":"88","author":"S Kumar","year":"2003","unstructured":"Kumar S, Bahn RS . Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 2003; 88: 4246\u20134250.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR3","first-page":"203","volume":"61","author":"N Laban-Guceva","year":"2007","unstructured":"Laban-Guceva N, Bogoev M, Antova M . Serum concentrations of interleukin (IL-)1alpha, 1beta, 6 and tumor necrosis factor (TNF-) alpha in patients with thyroid eye disease (TED). Med Arh 2007; 61: 203\u2013206.","journal-title":"Med Arh"},{"key":"BFeye2012284_CR4","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2353\/ajpath.2006.060434","volume":"169","author":"SE Feldon","year":"2006","unstructured":"Feldon SE, O\u2019loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP . Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol 2006; 169: 1183\u20131193.","journal-title":"Am J Pathol"},{"key":"BFeye2012284_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.survophthal.2009.06.009","volume":"55","author":"VM Naik","year":"2010","unstructured":"Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS . Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol. 2010; 55: 215\u2013226.","journal-title":"Surv Ophthalmol."},{"key":"BFeye2012284_CR6","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJM199311113292007","volume":"329","author":"RS Bahn","year":"1993","unstructured":"Bahn RS, Heufelder AE . Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993; 329: 1468\u20131475.","journal-title":"N Engl J Med"},{"key":"BFeye2012284_CR7","first-page":"302","volume":"69","author":"MR Soeters","year":"2011","unstructured":"Soeters MR, van Zeijl CJ, Boelen A, Kloos R, Saeed P, Vriesendorp TM et al. Optimal management of Graves orbitopathy: a multidisciplinary approach. Neth J Med 2011; 69: 302\u2013308.","journal-title":"Neth J Med"},{"key":"BFeye2012284_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/jc.2006-1824","volume":"92","author":"TJ Cawood","year":"2007","unstructured":"Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D . Smoking and Thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab 2007; 92: 59\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2265.2005.02186.x","volume":"62","author":"CB Terwee","year":"2005","unstructured":"Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM . Measuring disease activity to predict therapeutic outcome in Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 2005; 62: 145\u2013155.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BFeye2012284_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1210\/jcem.74.4.1532179","volume":"74","author":"AE Heufelder","year":"1992","unstructured":"Heufelder AE, Wenzel BE, Bahn RS . Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves\u2019 retroocular fibroblasts. J Clin Endocrinol Metab 1992; 74: 737\u2013742.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1006\/exer.1997.0353","volume":"65","author":"HB Burch","year":"1997","unstructured":"Burch HB, Lahiri S, Bahn RS, Barnes S . Superoxide radical production stimulates retroocular fibroblast proliferation in Graves\u2019 ophthalmopathy. Exp Eye Res 1997; 65: 311\u2013316.","journal-title":"Exp Eye Res"},{"key":"BFeye2012284_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/thy.1999.9.297","volume":"9","author":"R Lu","year":"1999","unstructured":"Lu R, Wang P, Wartofsky L, Sutton BD, Zweier JL, Bahn RS et al. Oxygen free radicals in interleukin-1betainduced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves\u2019 ophthalmopathy patients. Thyroid 1999; 9: 297\u2013303.","journal-title":"Thyroid"},{"key":"BFeye2012284_CR13","first-page":"1","volume":"22","author":"NE Dehina","year":"2009","unstructured":"Dehina NE, Minich W, Behrends T, Morgenthaler NG, Kohrle J, Schomburg L . Circulating selenoprotein P concentrations are decreased in patients with Graves\u2019 disease and correlate inversely to severity of orbitopathy. Acta Med Port 2009; 22: 1.","journal-title":"Acta Med Port"},{"key":"BFeye2012284_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mnfr.200700330","volume":"52","author":"PR Hoffmann","year":"2008","unstructured":"Hoffmann PR, Berry MJ . The influence of selenium on immune responses. Mol Nutr Food Res 2008; 52: 1273\u20131280.","journal-title":"Mol Nutr Food Res"},{"key":"BFeye2012284_CR15","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M et alEuropean Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011; 364: 1920\u20131931.","journal-title":"N Engl J Med"},{"key":"BFeye2012284_CR16","doi-asserted-by":"publisher","first-page":"736161","DOI":"10.1155\/2012\/736161","volume":"2012","author":"LH Duntas","year":"2012","unstructured":"Duntas LH . The evolving role of selenium in the treatment of Graves' disease and ophthalmopathy. J Thyroid Res 2012; 2012: 736161.","journal-title":"J Thyroid Res"},{"key":"BFeye2012284_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C et alEuropean Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158: 273\u2013285.","journal-title":"Eur J Endocrinol"},{"key":"BFeye2012284_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/thy.2007.0315","volume":"18","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008; 18: 333\u2013346.","journal-title":"Thyroid"},{"key":"BFeye2012284_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/imj.1962.11.2.113","volume":"11","author":"IB Hales","year":"1962","unstructured":"Hales IB, Thomas ID . Treatment of thyroid ophthalmopathy with corticoid analogues. Australas Ann Med 1962; 11: 113\u2013117.","journal-title":"Australas Ann Med"},{"key":"BFeye2012284_CR20","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1210\/jc.2011-0307","volume":"96","author":"WM Wiersinga","year":"2011","unstructured":"Wiersinga WM . Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? Clin Endocrinol Metab 2011; 96: 2386\u20132394.","journal-title":"Clin Endocrinol Metab"},{"key":"BFeye2012284_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ . Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011; 96: 320\u2013332.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR22","first-page":"3562","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell\u2019Unto E, Rocchi R et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001; 86: 3562\u20133567.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C et al. Consensus statement of the European Group on Graves\u2019orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158: 273\u2013285.","journal-title":"Eur J Endocrinol"},{"key":"BFeye2012284_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/105072504774193276","volume":"14","author":"M Marin\u00f3","year":"2004","unstructured":"Marin\u00f3 M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C . Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004; 14: 403\u2013406.","journal-title":"Thyroid"},{"key":"BFeye2012284_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1089\/thy.2000.10.521","volume":"10","author":"M Weissel","year":"2000","unstructured":"Weissel M, Hauff W . Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000; 10: 521.","journal-title":"Thyroid"},{"key":"BFeye2012284_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1385\/ENDO:29:3:513","volume":"29","author":"A Gursoy","year":"2006","unstructured":"Gursoy A, Cesur M, Erdogan MF, Corapcioglu D, Kamel N . New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy. Endocrine 2006; 29: 513\u2013516.","journal-title":"Endocrine"},{"key":"BFeye2012284_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.14310\/horm.2002.1323","volume":"10","author":"S Tigas","year":"2011","unstructured":"Tigas S, Papachilleos P, Ligkros N, Andrikoula M, Tsatsoulis A . Hypokalemic paralysis following administration of intravenous methylprednisolone in a patient with Graves' thyrotoxicosis and ophthalmopathy. Hormones (Athens) 2011; 10: 313\u2013316.","journal-title":"Hormones (Athens)"},{"key":"BFeye2012284_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1089\/thy.2010.0158","volume":"22","author":"H Wichary","year":"2012","unstructured":"Wichary H, Gasi\u0144ska T . Methylprednisolone and hepatotoxicity in graves' ophthalmopathy. Thyroid 2012; 22: 64\u201369.","journal-title":"Thyroid"},{"key":"BFeye2012284_CR29","first-page":"120","volume-title":"Graves' Orbitopathy. A multidisciplinary Approach\u2013Questions and Answers","author":"GJ Kahaly","year":"2010","unstructured":"Kahaly GJ . Management of moderately severe Graves\u2019 orbitopathy. In Wiersinga WM, Kahaly GJ (eds) Graves' Orbitopathy. A multidisciplinary Approach\u2013Questions and Answers 2nd Edn, Karger Basel, 2010 pp 120\u2013155."},{"key":"BFeye2012284_CR30","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M . Randomized, single blind trial of intravenous versus oral glucocorticoid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 2005; 90: 5234\u20135240.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","volume":"61","author":"S Aktaran","year":"2007","unstructured":"Aktaran S, Akarsu E, Erba\u011fci I, Araz M, Okumu\u015f S, Kartal M . Comparison of intravenous methylprednisolone therapy vs oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract 2007; 61: 45\u201351.","journal-title":"Int J Clin Pract"},{"key":"BFeye2012284_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1530\/acta.0.1220008","volume":"122","author":"P Perros","year":"1990","unstructured":"Perros P, Weightman DR, Crombie AL, Kendall-Taylor P . Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinologica 1990; 122: 8\u201312.","journal-title":"Acta Endocrinologica"},{"key":"BFeye2012284_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1745-6215-9-6","volume":"9","author":"R Rajendram","year":"2008","unstructured":"Rajendram R, Lee RW, Potts MJ, Rose GE, Jain R, Olver JM et al. Protocol for the combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. Trials 2008; 9: 6.","journal-title":"Trials"},{"key":"BFeye2012284_CR34","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"MF Prummel","year":"1989","unstructured":"Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. New England Journal of Medicine 1989; 321: 1353\u20131359.","journal-title":"New England Journal of Medicine"},{"key":"BFeye2012284_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/ICU.0b013e3283499446","volume":"22","author":"RS Douglas","year":"2011","unstructured":"Douglas RS, Gupta S . The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol 2011; 22: 385\u2013390.","journal-title":"Curr Opin Ophthalmol"},{"key":"BFeye2012284_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12016-007-8024-3","volume":"34","author":"P Bonara","year":"2008","unstructured":"Bonara P, Vannucchi G, Campi I, Rossi S, Cantoni F, Frugoni C et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clin Rev Allergy Immunol 2008; 34: 118\u2013123.","journal-title":"Clin Rev Allergy Immunol"},{"key":"BFeye2012284_CR37","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1517\/14712598.7.7.1061","volume":"7","author":"CH Nielsen","year":"2007","unstructured":"Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Heged\u00fcs L . B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther 2007; 7: 1061\u20131078.","journal-title":"Expert Opin Biol Ther"},{"key":"BFeye2012284_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ando.2008.02.013","volume":"69","author":"M Salvi","year":"2008","unstructured":"Salvi M, Vannucchi G, Campi I, Curr\u00f2 N, Beck-Peccoz P . New immunomodulators in the treatment of Graves' ophthalmopathy. Ann Endocrinol (Paris) 2008; 69: 153\u2013156.","journal-title":"Ann Endocrinol (Paris)"},{"key":"BFeye2012284_CR39","first-page":"457","volume":"109","author":"J Komorowski","year":"2007","unstructured":"Komorowski J, Jankiewicz-Wika J, Siejka A, Lawnicka H, Klysik A, Gos R et al. Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy. Klin Oczna 2007; 109: 457\u2013460.","journal-title":"Klin Oczna"},{"key":"BFeye2012284_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/01676830590912562","volume":"24","author":"OM Durrani","year":"2005","unstructured":"Durrani OM, Reuser TQ, Murray PI . Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005; 24: 117\u2013119.","journal-title":"Orbit"},{"key":"BFeye2012284_CR41","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","volume":"19","author":"D Paridaens","year":"2005","unstructured":"Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM . The effect of Etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005; 19: 1286\u20131289.","journal-title":"Eye"},{"key":"BFeye2012284_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1034\/j.1399-0039.1999.540307.x","volume":"54","author":"DH Verity","year":"1999","unstructured":"Verity DH, Wallace GR, Vaughan RW, Ohno S, Kondeatis E, Madanat W et al. HLA and TNF polymorphisms in ocular Beh\u00e7et\u2019s disease. Tissue Antigens 1999; 54: 264\u2013272.","journal-title":"Tissue Antigens"},{"issue":"Suppl 5","key":"BFeye2012284_CR43","first-page":"S201","volume":"107","author":"GJ Kahaly","year":"1999","unstructured":"Kahaly GJ, Roesler HP, Kutzner J, Pitz S, Muller-Forell W, Beyer J et al. Radiotherapy for thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl 5): S201\u2013S207.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"BFeye2012284_CR44","first-page":"102","volume":"85","author":"GJ Kahaly","year":"2000","unstructured":"Kahaly GJ, Rosler HP, Pitz S, Hommel G . Low- versus high-dose radiotherapy for Graves\u2019 ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000; 85: 102\u2013108.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/105072502753600223","volume":"12","author":"L Bartalena","year":"2002","unstructured":"Bartalena L, Marcocci C, Tanda ML, Rocchi R, Mazzi B, Barbesino G et al. Orbital radiotherapy for Graves' ophthalmopathy. Thyroid 2002; 12: 245\u2013250.","journal-title":"Thyroid"},{"key":"BFeye2012284_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1210\/jc.2003-030809","volume":"89","author":"MF Prummel","year":"2004","unstructured":"Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 2004; 89: 15\u201320.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR47","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2003-030260","volume":"88","author":"C Marcocci","year":"2003","unstructured":"Marcocci C, Bartalena L, Rocchi R, Marin\u00f2 M, Menconi F, Morabito E et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003; 88: 3561\u20133566.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFeye2012284_CR48","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ajo.2005.12.010","volume":"141","author":"SL Liao","year":"2006","unstructured":"Liao SL, Chang TC, Lin LL . Transcaruncular orbital decompression: an alternate procedure for Graves ophthalmopathy with compressive optic neuropathy. Am J Ophthalmol 2006; 141: 810\u2013818.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2012284_CR49","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ajo.2006.01.066","volume":"141","author":"JD McCann","year":"2006","unstructured":"McCann JD, Goldberg RA, Anderson RL, Burroughs JR, Ben Simon GJ . Medial wall decompression for optic neuropathy but lateral wall decompression with fat removal for non vision-threatening indications. Am J Ophthalmol 2006; 141: 916\u2013917.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2012284_CR50","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.otc.2006.01.004","volume":"39","author":"R Metson","year":"2006","unstructured":"Metson R, Pletcher SD . Endoscopic orbital and optic nerve decompression. Otolaryngol Clin North Am 2006; 39: 551\u2013561.","journal-title":"Otolaryngol Clin North Am"},{"key":"BFeye2012284_CR51","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/00055735-200210000-00004","volume":"13","author":"DE Siracuse-Lee","year":"2002","unstructured":"Siracuse-Lee DE, Kazim M . Orbital decompression: current concepts. Curr Opin Ophthalmol. 2002; 13: 310\u2013316.","journal-title":"Curr Opin Ophthalmol."},{"key":"BFeye2012284_CR52","first-page":"165","volume":"54","author":"P Eloy","year":"2000","unstructured":"Eloy P, Trussart C, Jouzdani E, Collet S, Rombaux P, Bertrand B . Transnasal endoscopic orbital decompression and Graves' ophtalmopathy. Acta Otorhinolaryngol Belg 2000; 54: 165\u2013174.","journal-title":"Acta Otorhinolaryngol Belg"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2012284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2012284","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2012284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:17:57Z","timestamp":1684415877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2012284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,15]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["BFeye2012284"],"URL":"https:\/\/doi.org\/10.1038\/eye.2012.284","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,15]]}}}